BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 11340074)

  • 1. Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53: evidence for the role of p300 in integrating ubiquitination and proteolysis.
    Zhu Q; Yao J; Wani G; Wani MA; Wani AA
    J Biol Chem; 2001 Aug; 276(32):29695-701. PubMed ID: 11340074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyubiquitination of p53 by a ubiquitin ligase activity of p300.
    Grossman SR; Deato ME; Brignone C; Chan HM; Kung AL; Tagami H; Nakatani Y; Livingston DM
    Science; 2003 Apr; 300(5617):342-4. PubMed ID: 12690203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of p53 degradation by Mdm2 acetylation.
    Wang X; Taplick J; Geva N; Oren M
    FEBS Lett; 2004 Mar; 561(1-3):195-201. PubMed ID: 15013777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stabilization and activation of p53 by the coactivator protein TAFII31.
    Buschmann T; Lin Y; Aithmitti N; Fuchs SY; Lu H; Resnick-Silverman L; Manfredi JJ; Ronai Z; Wu X
    J Biol Chem; 2001 Apr; 276(17):13852-7. PubMed ID: 11278372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p300/MDM2 complexes participate in MDM2-mediated p53 degradation.
    Grossman SR; Perez M; Kung AL; Joseph M; Mansur C; Xiao ZX; Kumar S; Howley PM; Livingston DM
    Mol Cell; 1998 Oct; 2(4):405-15. PubMed ID: 9809062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 mediates p300/CREB-binding protein-associated factor ubiquitination and degradation.
    Jin Y; Zeng SX; Lee H; Lu H
    J Biol Chem; 2004 May; 279(19):20035-43. PubMed ID: 14769800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 suppresses p73 function without promoting p73 degradation.
    Zeng X; Chen L; Jost CA; Maya R; Keller D; Wang X; Kaelin WG; Oren M; Chen J; Lu H
    Mol Cell Biol; 1999 May; 19(5):3257-66. PubMed ID: 10207051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2.
    Maki CG
    J Biol Chem; 1999 Jun; 274(23):16531-5. PubMed ID: 10347217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.
    Rodriguez MS; Desterro JM; Lain S; Lane DP; Hay RT
    Mol Cell Biol; 2000 Nov; 20(22):8458-67. PubMed ID: 11046142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation.
    Zhou BP; Liao Y; Xia W; Zou Y; Spohn B; Hung MC
    Nat Cell Biol; 2001 Nov; 3(11):973-82. PubMed ID: 11715018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of the p300-dependent mdm2 negative-feedback loop induces the p53 apoptotic function.
    Thomas A; White E
    Genes Dev; 1998 Jul; 12(13):1975-85. PubMed ID: 9649502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination.
    Nie L; Sasaki M; Maki CG
    J Biol Chem; 2007 May; 282(19):14616-25. PubMed ID: 17371868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding.
    Inoue T; Geyer RK; Howard D; Yu ZK; Maki CG
    J Biol Chem; 2001 Nov; 276(48):45255-60. PubMed ID: 11572869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of an E1A-CBP interaction defines a novel transcriptional adapter motif (TRAM) in CBP/p300.
    O'Connor MJ; Zimmermann H; Nielsen S; Bernard HU; Kouzarides T
    J Virol; 1999 May; 73(5):3574-81. PubMed ID: 10196247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM2-dependent ubiquitination of nuclear and cytoplasmic P53.
    Yu ZK; Geyer RK; Maki CG
    Oncogene; 2000 Nov; 19(51):5892-7. PubMed ID: 11127820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression.
    Wadgaonkar R; Collins T
    J Biol Chem; 1999 May; 274(20):13760-7. PubMed ID: 10318779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination.
    Nakamura S; Roth JA; Mukhopadhyay T
    Mol Cell Biol; 2000 Dec; 20(24):9391-8. PubMed ID: 11094089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter specificity and stability control of the p53-related protein p73.
    Lee CW; La Thangue NB
    Oncogene; 1999 Jul; 18(29):4171-81. PubMed ID: 10435630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification.
    Knights CD; Liu Y; Appella E; Kulesz-Martin M
    J Biol Chem; 2003 Dec; 278(52):52890-900. PubMed ID: 14555661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress.
    Grönroos E; Terentiev AA; Punga T; Ericsson J
    Proc Natl Acad Sci U S A; 2004 Aug; 101(33):12165-70. PubMed ID: 15295102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.